<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>18(8)</volume><submitter>Otake-Kasamoto Y</submitter><pubmed_abstract>&lt;h4>Background and aim&lt;/h4>Colonoscopy is necessary for diagnosing and surveilling patients with ulcerative colitis, though it may cause disease flares. Colonoscopy with carbon dioxide (CO2) insufflation decreases abdominal discomfort; however, its effect on exacerbation incidence in ulcerative colitis remains unclear. Therefore, this study aimed to evaluate the colonoscopy effects using CO2 insufflation in patients with ulcerative colitis.&lt;h4>Methods&lt;/h4>Overall, 96 remissive patients with ulcerative colitis (partial Mayo score ≤ 2) who underwent total colonoscopy between March 2015 and December 2019 at Osaka University Hospital were enrolled and blindly randomized to the CO2 (n = 45) and air (n = 51) insufflation group (UMIN-CTR, number: UMIN000018801). The post-procedural abdominal discomfort and the clinical relapse (partial Mayo score ≥ 3) rate within 8 weeks were evaluated.&lt;h4>Results&lt;/h4>Baseline backgrounds did not differ between the groups. The mean abdominal fullness and pain scores were significantly lower in the CO2 group than in the Air group immediately (p = 0.0003, p = 0.0003) and 30 min (p &lt; 0.0001, p &lt; 0.0001) after colonoscopy. While the overall clinical relapse rate remained unchanged between the groups, the clinical relapse rate at 8 weeks after colonoscopy was significantly lower in the CO2 group than in the Air group in patients not in complete remission (Mayo endoscopic subscore ≥ 1, p = 0.049; or partial Mayo score ≥ 1, p = 0.022).&lt;h4>Conclusions&lt;/h4>CO2 insufflation can reduce abdominal discomfort in remissive patients with ulcerative colitis and decrease clinical relapse at 8 weeks after colonoscopy for those not in complete remission.</pubmed_abstract><journal>PloS one</journal><pagination>e0290329</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10434883</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Carbon dioxide insufflation reduces the relapse of ulcerative colitis after colonoscopy: A randomized controlled trial.</pubmed_title><pmcid>PMC10434883</pmcid><pubmed_authors>Inoue T</pubmed_authors><pubmed_authors>Hayashi Y</pubmed_authors><pubmed_authors>Kawai S</pubmed_authors><pubmed_authors>Shinzaki S</pubmed_authors><pubmed_authors>Tashiro T</pubmed_authors><pubmed_authors>Tsujii Y</pubmed_authors><pubmed_authors>Tani M</pubmed_authors><pubmed_authors>Amano T</pubmed_authors><pubmed_authors>Hiyama S</pubmed_authors><pubmed_authors>Yoshii S</pubmed_authors><pubmed_authors>Iijima H</pubmed_authors><pubmed_authors>Takehara T</pubmed_authors><pubmed_authors>Otake-Kasamoto Y</pubmed_authors><pubmed_authors>Yoshihara T</pubmed_authors></additional><is_claimable>false</is_claimable><name>Carbon dioxide insufflation reduces the relapse of ulcerative colitis after colonoscopy: A randomized controlled trial.</name><description>&lt;h4>Background and aim&lt;/h4>Colonoscopy is necessary for diagnosing and surveilling patients with ulcerative colitis, though it may cause disease flares. Colonoscopy with carbon dioxide (CO2) insufflation decreases abdominal discomfort; however, its effect on exacerbation incidence in ulcerative colitis remains unclear. Therefore, this study aimed to evaluate the colonoscopy effects using CO2 insufflation in patients with ulcerative colitis.&lt;h4>Methods&lt;/h4>Overall, 96 remissive patients with ulcerative colitis (partial Mayo score ≤ 2) who underwent total colonoscopy between March 2015 and December 2019 at Osaka University Hospital were enrolled and blindly randomized to the CO2 (n = 45) and air (n = 51) insufflation group (UMIN-CTR, number: UMIN000018801). The post-procedural abdominal discomfort and the clinical relapse (partial Mayo score ≥ 3) rate within 8 weeks were evaluated.&lt;h4>Results&lt;/h4>Baseline backgrounds did not differ between the groups. The mean abdominal fullness and pain scores were significantly lower in the CO2 group than in the Air group immediately (p = 0.0003, p = 0.0003) and 30 min (p &lt; 0.0001, p &lt; 0.0001) after colonoscopy. While the overall clinical relapse rate remained unchanged between the groups, the clinical relapse rate at 8 weeks after colonoscopy was significantly lower in the CO2 group than in the Air group in patients not in complete remission (Mayo endoscopic subscore ≥ 1, p = 0.049; or partial Mayo score ≥ 1, p = 0.022).&lt;h4>Conclusions&lt;/h4>CO2 insufflation can reduce abdominal discomfort in remissive patients with ulcerative colitis and decrease clinical relapse at 8 weeks after colonoscopy for those not in complete remission.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023</publication><modification>2025-04-05T14:51:27.381Z</modification><creation>2025-04-05T14:51:27.381Z</creation></dates><accession>S-EPMC10434883</accession><cross_references><pubmed>37590283</pubmed><doi>10.1371/journal.pone.0290329</doi></cross_references></HashMap>